[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nutrition-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nutrition-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100396043","phase-3-effect-of-standard-nutrition-therapy-on-nutritional-status-and-prognosis-in-locoregionally-advanced-nasopharyngeal-carcinoma-patients-with-malnutrition-100396043",false,"NCT04436965","Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition","Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition: A Prospective, Multicenter, Phase III Randomized Control Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II\u002FIII);\n* All genders，range from 18～65 years old;\n* Karnofsky performance status(KPS) ≥ 80;\n* Clinical stage III\\~IVa(AJCC\u002FUICC 8th);\n* Without significant digestive system disease，nutritional and metabolic diseases or endocrine disease\n* Without significant cardiac，respiratory，kidney or liver disease;\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy);\n* White blood cell(WBC) count ≥ 4×109\u002FL, neutrophile granulocyte(NE) count ≥ 1.5×109\u002FL, Hemoglobin(HGB) ≥ 9g\u002FL, platelet(PLT) count ≥ 100×109\u002FL\n* Total bilirubin(TBIL)、alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \\\u003C 2.5×upper limit of normal(ULN);\n* Adequate renal function: BUN\u002FCRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* No contraindications to chemotherapy or radiotherapy;\n* Inform consent form;\n\nExclusion Criteria:\n\n* Have some PEG\u002FPEJ contraindications, such as coagulopathy, recent anticoagulant medications and aspirin, gastric ulcer or history of gastric bleeding, portal hypertension combined with abdominal and esophageal fundal varices, pyloric obstruction due to residual stomach under the costal arch after various major gastrectomy or various reasons;\n* Distance metastases;\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts;\n* Mental disorder;\n* Pregnancy or lactation;\n* Severe complication, eg, uncontrolled hypertension;","ALL","18 Years","65 Years",{"count":20,"type":21},266,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced nasopharyngeal carcinoma patients.",[27,28],"Nasopharyngeal Carcinoma","Nutrition Therapy","RECRUITING","2026-05-06",{"date":32,"type":33},"2026-05-11","ACTUAL",{"date":35,"type":33},"2021-08-16",{"date":37,"type":21},"2029-12",{"name":39,"class":40},"Sun Yat-sen University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":41},"100417430","multicomponent-prehabilitation-and-outcomes-in-elderly-patients-with-frailty-100417430","NCT04715581","Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty","Effect of Multicomponent Prehabilitation on Early and Long-term Outcomes in Elderly Patients With Frailty After Digestive Surgery for Cancer: A Randomized-controlled Study","Inclusion criteria:\n\n1. Age ≥65 years but \\\u003C90 years;\n2. Scheduled to undergo major surgery for digestive cancer with an expected duration of 2 hours and longer, including cancers of esophagus, stomach, small intestine, colon, rectum, pancreas, liver, and biliary tract;\n3. Clinical Frailty Scale ≥5;\n4. Provide written informed consent.\n\nExclusion Criteria:\n\n1. Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;\n2. Inability to communicate due to coma, profound dementia, or language barrier;\n3. Inability to participate in preoperative rehabilitation due to paralysis, fracture or other movement disorder;\n4. Inability to take oral diet due to preoperative gastrointestinal disease or other disease;\n5. Severe heart dysfunction (left ventricular ejection fraction \\\u003C30% or New York Heart Association classification IV), severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (undergoing dialysis before surgery), or American Society of Anesthesiologists classification of grade 4 or higher;\n6. Other reasons that are considered unsuitable for study participation.","89 Years",{"count":51,"type":21},540,[53],"NA","The study is designed to investigate the effect of a multicomponent prehabilitation pathway on early and long-term outcomes in elderly patients with frailty recovering from surgery for digestive cancer.",[56,57,58,59,28,60],"Old Age; Debility","Digestive Cancer","Surgery","Preoperative Rehabilitation","Outcomes",[62,63,64,65,66,67],"older patients","frailty","digestive cancer","prehabilitation","nutrition therapy","outcomes","2025-07-29",{"date":70,"type":33},"2025-07-31",{"date":72,"type":33},"2021-11-25",{"date":74,"type":21},"2028-12",{"name":76,"class":40},"Peking University First Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100587924","meal-frequency-and-glycemic-control-in-individuals-with-type-1-diabetes-100587924","NCT06934707","Meal Frequency and Glycemic Control in Individuals With Type 1 Diabetes","Meal Frequency, Glycemic Control and Variability in Individuals With Type 1 Diabetes: a Randomized Crossover Clinical Trial","Inclusion Criteria:\n\n* • Adults (18 to 60 years old) with a medical diagnosis of type 1 diabetes mellitus\n\n  * Individuals who perform carbohydrate counting\n  * Individuals diagnosed \\> 12 months ago\n  * Perform daily glycemic control using a blood glucose monitor or use of a glucose sensor\n  * Have the ability to understand and be able to adhere to the proposed interventions.\n  * Complete a detailed 3-day food record for one week prior to the intervention and record episodes of hypoglycemia (\\\u003C70 mg\u002FdL) and hyperglycemia (\\>180 mg\u002FdL)\n  * Able and willing to provide written informed consent and comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n* Individuals with glycated hemoglobin ≥ 11%\n* Individuals who are using NPH insulin\n* Retinopathy with vision deficit that limits the activities proposed in the disciplines.\n* Individuals with gastrointestinal disease such as celiac disease, Crohn's disease and Irritable Bowel Syndrome (IBS)\n* History of bariatric surgery\n* That you are following a carbohydrate, protein and\u002For fat restriction diet\n* Individuals with BMI ≥ 40kg\u002Fm2\n* Chronic kidney disease with estimated glomerular filtration \\\u003C30mL\u002Fmin per 1.73 m2.\n* Liver failure or chronic viral hepatitis\n* Active or progressive neurodegenerative disease\n* Use of medications that affect glucose metabolism (corticosteroids and immunosuppressants) or cause weight loss. ● Treatment with weight-reducing agents (e.g., orlistat, sibutramine, topiramate, liraglutide) in the last 12 weeks prior to screening.\n* Treatment with thyroid hormone that has not been maintained at a stable dose in the last 12 weeks prior to screening.\n* History of active substance abuse (including alcohol) in the last year.\n* Serious psychiatric illness: Mood disorders, anxiety disorders, severe psychotic disorders, and personality disorders that are revealed or identified in the clinical evaluation, listed or reported in the medical record, and that have no clinical findings.\n* Predisposition to or diagnosis of eating disorders.\n* Women who are pregnant, intending to become pregnant during the study period, or who are breastfeeding.\n* Hyperglycemia characterized by acute symptoms: polyuria, polydipsia, and\u002For weight loss in the last 3 months. ● Metabolic and acute complications of diabetes such as ketoacidosis or hyperosmolar coma.\n* Night workers who work after 10 pm.",{"count":85,"type":21},27,[53],"The goal of this clinical trial is to examine the effect of 3 versus 6 daily meals of isocaloric diets on glycemic control and variability in individuals with type 1 diabetes. Participants will be randomized in a crossover clinical trial and will receive two different types of isocaloric diet interventions, in 3 meals\u002Fday (calorie distribution: 30% at breakfast, 40% at lunch and 30% at dinner) or 6 meals\u002Fday (calorie distribution: 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 25% at dinner and 5% at evening snack), for three weeks, with a 4-week washout period between diets.",[89,28,90],"Type 1 Diabetes (T1D)","Glycemic Control for Diabetes Mellitus",[92,93,94,95],"type 1 Diabetes","glycemic control","diet","meal frequency","NOT_YET_RECRUITING","2025-04-11",{"date":99,"type":33},"2025-04-18",{"date":101,"type":21},"2025-04-20",{"date":103,"type":21},"2027-12-29",{"name":105,"class":40},"Hospital de Clinicas de Porto Alegre"]